This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
VIA AILooking for an interpreter?
Remoto by ProZ.com connects you with an identity-verified interpreter by video or phone in about 60 seconds — 300+ languages, on demand or booked ahead.
Try Remoto »
Working languages:
French to English
Client-vendor relationship recorded successfully!
Richard May has been added to your list of hired vendors.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Science (general)
Medical: Pharmaceuticals
Biology (-tech,-chem,micro-)
Medical: Instruments
Medical (general)
Medical: Health Care
Rates
General rate: 0.12 EUR per word / 25 EUR per hour
Rates per language pair: French to English - Rates: 0.12 - 0.18 EUR per word / 30 - 45 EUR per hour
Payment methods accepted
Wire transfer
Portfolio
Sample translations submitted: 1
French to English: Phase III study assessing the maintenance of disease control by the continuation of drug B in maintenance therapy or by the sequential introduction of drug C, in patients suffering from metastatic Non-Small Cell Lung Cancer (NSCLC) controlled after induct General field: Medical
Source text - French Les résultats de la chimiothérapie de 1ère ligne dans les cancers bronchiques non à petites cellules (CBNPC) avancés demeurent décevants malgré l'introduction des cytotoxiques de 3ème génération (médiane de survie de 7,9 mois et survie à 1 an de 33%). La durée du contrôle de la maladie reste faible avec un temps médian jusqu'à progression de 3,7 mois. Deux voies peuvent être explorées pour tenter d'augmenter la durée du contrôle de la maladie, objectif prioritaire dans le traitement palliatif de cette maladie :
• chimiothérapie de maintenance en prolongeant l'administration du médicament A, drogue dépourvue de toxicité cumulative non hématologique chez des patients stabilisés ou en réponse après chimiothérapie de 1ère ligne par médicament A médicament B ; cette stratégie a montré qu'elle pouvait significativement augmenter le temps jusqu'à progression dans l'unique essai de phase III testant cette hypothèse;
• introduction séquentielle du médicament C, inhibiteur de la tyrosine kinase de l'EGFR. Le médicament C en monothérapie de seconde ou 3ème ligne a démontré une augmentation significative de la survie par rapport à un placebo dans l'essai de phase III BR21 ; bien que les facteurs prédictifs de réponse au médicament C soient dans cette étude le sexe féminin, l'histologie de type adénocarcinome et l'absence de tabagisme, l'effet bénéfique sur la survie du médicament C s'exerce de façon homogène quels que soient le sexe ou l'histologie. L'administration simultanée d'une chimiothérapie et du médicament C en 1ère ligne de traitement n'apporte en revanche aucun bénéfice par rapport à la chimiothérapie seule dans les 2 essais de phase III (Talent et Tribute); cependant, l'analyse de la survie en landmark de l'essai Tribute à 6 mois, soit après l'arrêt de la chimiothérapie, montre un bénéfice significatif de survie pour les patients poursuivant du médicament C en monothérapie par rapport au placebo, constituant un argument important en faveur de l'administration séquentielle des inhibiteurs de la TK de l'EGFR après chimiothérapie cytotoxique. L'administration orale et un profil de tolérance favorable font du médicament C un bon candidat à une telle administration séquentielle.
Translation - English The results of first-line chemotherapy in advanced Non-Small Cell Lung Cancer (NSCLC) remain disappointing despite the introduction of 3rd generation cytotoxics (survival median of 7.9 months and 33% survival at 1 year). The duration of disease control remains poor with a median time of 3.7 months until progression. Two paths can be explored to try and increase the duration of disease control, a priority objective in the palliative treatment of this disease:
• maintenance chemotherapy by prolonging the administration of drug A, drug lacking in cumulative non-haematological toxicity in stabilised patients or responding after first-line chemotherapy with drug A drug B; this strategy has shown that it can significantly increase the time until progression in the only phase III trial testing this hypothesis;
• sequential introduction of drug C, an EGFR tyrosine kinase inhibitor. Drug C in second- or third-line monotherapy has shown a significant increase in survival compared to placebo in the phase III trial BR21; although the predictive response factors to drug C in this study were female gender, adenocarcinoma histology and non-smoking status, the beneficial effects of drug C on survival was homogenous regardless of the gender or the histology. On the other hand, the simultaneous administration of chemotherapy and drug C in first-line treatment brings no benefit compared to chemotherapy alone in 2 phase III trials (Talent and Tribute); however, the landmark survival analysis at 6 months for the Tribute trial, after the end of chemotherapy, shows a significant benefit in survival for patients continuing on drug C monotherapy compared to placebo, which is a strong argument in favour of the sequential administration of EGFR TK inhibitors after cytotoxic chemotherapy. The oral administration and a favourable safety profile make drug C a good candidate for sequential administration.
More
Less
Experience
Years of experience: 1. Registered at ProZ.com: Jan 2012.
I am a trained biochemist working as a freelance translator from French to English specialising in scientific, biotechnical and clinical trial documents.
Prior to becoming a translator, I worked as a Clinical Research Associate in public hospitals in France for 4 years. I worked in Lyon on protocols sponsored by the Hospices Civils de Lyon, gaining extensive experience in French clinical regulations and monitoring of studies over a wide range of specialities. I also worked as a Clinical Research Associate in the Psychiatric department of the CHU de Clermont-Ferrand.
For more details regarding my professional experience and qualifications, please refer to my CV.
Keywords: French, English, biochemistry, biology, medical, pharmaceutical, biotechnical, clinical research
Portfolio